COEP vs. CHRO, GENE, BCDA, TVGN, ONVO, SRNE, IKT, PMCB, NSTGQ, and SNTI
Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Chromocell Therapeutics (CHRO), Genetic Technologies (GENE), BioCardia (BCDA), Tevogen Bio (TVGN), Organovo (ONVO), Sorrento Therapeutics (SRNE), Inhibikase Therapeutics (IKT), PharmaCyte Biotech (PMCB), NanoString Technologies (NSTGQ), and Senti Biosciences (SNTI). These companies are all part of the "biological products, except diagnostic" industry.
Chromocell Therapeutics (NYSE:CHRO) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
In the previous week, Coeptis Therapeutics had 2 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 0 mentions for Chromocell Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.00 equaled Chromocell Therapeutics'average media sentiment score.
Coeptis Therapeutics' return on equity of 0.00% beat Chromocell Therapeutics' return on equity.
Chromocell Therapeutics has higher earnings, but lower revenue than Coeptis Therapeutics.
78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Coeptis Therapeutics has a consensus price target of $3.00, indicating a potential upside of 689.47%. Given Chromocell Therapeutics' higher possible upside, analysts clearly believe Coeptis Therapeutics is more favorable than Chromocell Therapeutics.
Coeptis Therapeutics received 5 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
Summary
Coeptis Therapeutics beats Chromocell Therapeutics on 6 of the 9 factors compared between the two stocks.
Get Coeptis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coeptis Therapeutics Competitors List
Related Companies and Tools
